Up to now, E-Health Now has established cooperation with hundreds of large-and medium-sized domestic financial-insurance institutions, delivering four major solution sets covering customer acquisition, value-added services, risk control and health-insurance-product innovation. We have also reached partnerships with nearly 200 banks and enterprises to provide employee health-management and welfare services, reaching tens of millions of end-users.

ABUIABACGAAg2t2dkwYo1_mGqgQwgEA4kTU
Cooperative Partner
Cooperation Cases

International Remote Video Consultation Facilitating Client Disease Recovery

Case 1
Consulting Physician：
Consultation Time：

Consultation Result：Director Lyu and Dr. Bradley McGregor discussed the client's condition, conducted a comprehensive analysis based on the patient's medical history and current symptoms, and compared all available options one by one, ultimately formulating a reasonable plan. On the second business day after the consultation, the client's family received the service report for this consultation and expressed great satisfaction with the service.

Director Lyu Wei, Urology Department, Feixian People's Hospital, Linyi City, Shandong Province


9:00 AM, December 19, 2019
Dr. Bradley McGregor, Genitourinary Oncology Specialist, Dana-Farber Cancer Institute, Harvard Medical School

Client: Client of Fosun-Prudential Life Insurance's "Star Satisfaction" Critical Illness Insurance

Condition Summary: A patient with a malignant tumor of the left renal pelvis combined with intrahepatic and retroperitoneal lymph node metastasis, accompanied by multiple villous adenomas in the sigmoid colon and ascending colon

Consultation Needed：Provided condition consultation for a urothelial carcinoma patient through international remote video consultation to clarify the next treatment plan

Consulting Physician：Director Lyu Wei, Urology Department, Feixian People's Hospital, Linyi City, Shandong Province
Case 2
Consulting Physician：
Consultation Time：
Consultation Result：First, the previous treatment plan was affirmed, putting the patient at ease. Professor Shan and Dr. Kathleen provided several recommendations for preventing breast cancer recurrence and metastasis: based on the 5-year endocrine regimen of ovarian function suppression plus AI (aromatase inhibitor), add zoledronic acid once every 6 months to reduce bone adverse events and improve prognosis; Professor Shan and Dr. Kathleen discussed the choice of aromatase inhibitor and ultimately selected anastrozole as the endocrine drug. Dr. Kathleen also emphasized the therapeutic value of CDK4/6 inhibitors in ER-positive, HER2-negative breast cancer. Additionally, the patient's own immunity against tumors should be regulated through increased exercise, dietary adjustment, adequate sleep, and psychological stress relief. Professor Shan also proposed that Traditional Chinese Medicine (TCM) might play a role in anti-tumor effects. Furthermore, the experts provided information on two ongoing drug clinical trials, offering references for further reducing the breast cancer recurrence rate.
Associate Chief Physician Shan Chengxiang, Breast and Thyroid Surgery Department, Shanghai Changzheng Hospital
9:00 AM, December 19, 2019
Dr. Kathleen K. Harnden, MD, PhD, Medical Oncology (Breast Cancer), Inova Health System

Client: VIP Client of Fosun-Prudential Life Insurance

Condition Summary: Only 38 years old, diagnosed with left breast invasive ductal carcinoma in February 2019, with two axillary lymph node metastases. The patient had undergone left breast modified radical mastectomy, TC×4 chemotherapy, radiotherapy, and endocrine therapy, with left breast reconstruction to follow

Consultation Needed：Regarding subsequent treatment plans, risk of disease recurrence and metastasis, and how to reduce the disease recurrence rate

Consulting Physician：Associate Chief Physician Shan Chengxiang, Breast and Thyroid Surgery Department, Shanghai Changzheng Hospital
Case 3
Consulting Physician：
Consultation Time：
Consultation Result： Based on the patient's current data, the main issue is diabetes insipidus, which can be caused by various diseases. In adolescents, the common cause is a pituitary tumor, with the possibility of a germ cell tumor (based on information such as the thickened pituitary stalk shown on MRI). The main need now is to control the symptoms of diabetes insipidus, which can be treated with vasopressin (desmopressin). The specific usage varies from person to person; start with a low dose and gradually adjust to find the appropriate dosage. Secondly, an enhanced cranial scan is recommended to further visualize the pituitary lesion. If germ cell tumor is ultimately confirmed, this tumor is particularly sensitive to radiotherapy and chemotherapy, and early detection often allows effective control or even cure through radiotherapy and chemotherapy.

Zhong Liyong, Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University

7:30 PM, November 4, 2020

Client: VIP Insurance User of ICBC-AXA Life Insurance

Condition Summary: Female, 9 years old, height 127 cm, weight 21.9 kg, with polydipsia and polyuria. Two weeks ago, home records showed 24-hour water intake of 5.6 L and urine output of 5.7 L. The November 2020 pituitary MRI showed: full pituitary morphology, uneven signal, thickened pituitary stalk, and no definite display of the posterior pituitary lobe. No other obvious abnormal indicators were observed.

Consultation Needed：Hoped to find an expert to review the condition, understand the cause of the current symptoms, and determine the treatment

Consulting Physician：Zhong Liyong, Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University
Case 4
Consulting Physician：
Consultation Time：
Consultation Result：1. Based on the genetic test results, the EGFR exon 21 L858R mutation allows first-line treatment with dacomitinib or osimertinib, which can be used without combining with chemotherapy temporarily. Since dacomitinib has been applied, it can be continued, with efficacy generally maintained for over a year. If drug resistance occurs, further genetic testing can be performed to check for new mutations. If the T790M mutation is present, treatment can be switched to osimertinib, with efficacy maintained for nearly a year. It is recommended to combine with radiotherapy for targeted radiation of mediastinal and pulmonary lesions, which would yield better results. After targeted therapy fails, chemotherapy combined with anti-angiogenic drugs and immunotherapy drugs can be used. 2. If radiotherapy is planned, PET-CT is recommended to further evaluate the lesion status, which is conducive to further precise radiotherapy. The examination time should be arranged as early as possible.

Director Wu Shikai, Oncology Department, Peking University First Hospital

9:00 AM, February 19, 2021

Client: VIP Insurance Client of PICC (People's Insurance Company of China) Shenzhen Branch

Condition Summary: A 55-year-old female patient with chest pain for 2 days. Chest CT showed: a small amount of left pleural effusion, multiple nodules in the left pleura, multiple pulmonary nodules, mediastinal lymph node enlargement, and multiple pulmonary inflammations. She was admitted on January 12, 2021 for anti-infective treatment with piperacillin-tazobactam, and underwent thoracentesis drainage and thoracoscopy. Results indicated: adenocarcinoma (left chest wall biopsy tissue), with genetic testing showing EGFR exon 21 L858R mutation. The local hospital planned chemotherapy combined with targeted drug therapy (pemetrexed combined with carboplatin).

Consultation Needed：Is the current treatment plan of pemetrexed combined with carboplatin chemotherapy and oral dacomitinib targeted therapy reasonable?

Consulting Physician：Director Wu Shikai, Oncology Department, Peking University First Hospital
Case 5
Medical Fast-track Service Process

Upon receiving the request, the company immediately arranged contact with the child's father to understand the child's condition and needs, and collected the child's medical records. The medical department matched a service plan based on the child's condition, recommending Director Huang Xiaojun from the Hematology Department of Peking University People's Hospital. After the plan was confirmed by the child's father, arrangements were made immediately, and Director Huang's outpatient appointment was successfully scheduled for two days later. The child is now hospitalized and receiving treatment at People's Hospital.

Client: VIP Client of Fosun United Health Insurance Company

Condition Summary: A one-and-a-half-year-old girl was locally diagnosed with very severe aplastic anemia. The condition was serious and might require bone marrow transplantation. The local doctor recommended finding specialists at a major hospital in Beijing for treatment.
©2026 华美浩联 版权所有

Address: Rooms 509 & 609, Building 237 Chaoyang North Road, Fosun International Center, Chaoyang District, Beijing

Tel: 400 807 9096

E-mail: hmhlservice@ehealthnow.cn
京ICP备17073763号-3

WeChat Official Account